Research explained · Reviewed September 15, 2026
Selank brings peptide biology into the study of anxiety and related symptoms. An early human comparison reported encouraging results, creating questions that are still useful for researchers to explore.
The human study behind the interest
A 2008 study compared Selank with medazepam in 62 patients with generalized anxiety disorder or neurasthenia. Thirty received Selank and 32 received the comparator. Researchers used established symptom scales and also measured an enkephalin-related biological parameter. They reported similar anxiety-relieving effects between groups, with additional effects on fatigue-related symptoms described for Selank. Read the clinical study abstract.
This is a useful starting point because it moves beyond laboratory mechanisms into measured symptoms in people. It should still be read as one small study, rather than a settled estimate of how well Selank works across anxiety conditions.
Why the comparison matters
An active comparator asks how two interventions perform against one another. A placebo-controlled trial asks a different question. Similar outcomes in a small study do not automatically establish equivalence: a trial designed to demonstrate equivalence needs an appropriate margin, sample size and analysis.
That distinction does not erase the encouraging observation. It tells us what type of evidence would make the finding more persuasive. A larger trial could test whether changes are reproducible, clinically meaningful and sustained after the study period.
Symptoms and signalling: two complementary views
The study’s combination of psychometric scales and a biological measurement is an appealing feature. A symptom scale can show whether people feel or function differently; a laboratory measure may help researchers investigate why. Neither should replace the other.
The diagnosis also matters. Generalized anxiety disorder and neurasthenia are not identical study populations, and “stress,” “focus” and “anxiety” are not interchangeable outcomes. A clear research question gives readers a better chance of understanding who the findings concern.
A constructive outlook
The strongest case for interest in Selank is the possibility of investigating peptide signalling alongside patient-centred outcomes. Future work can build on the early report by using larger groups, well-described masking, longer follow-up and independent replication. Reporting both favourable and unfavourable responses would help define where any benefit is most likely.
The original clinical paper is in Russian; the English abstract supports the focused summary above. Details not available there, including a complete appraisal of methods and adverse events, remain important to review. This is a promising question for research, not a basis for replacing an established anxiety-care plan.